Author
Reading time
Published
Categories
Gesynta Pharma AB has secured SEK 304 million in a Series B financing round led by Innovestor Life Science. The funding will primarily be used for a Phase II clinical trial of vipoglanstat – a drug candidate aimed at revolutionizing the treatment of the debilitating inflammatory disease endometriosis affecting 190 million women globally. The round attracted participation from new European and U.S. specialist investors while gaining strong support from existing shareholders.
Endometriosis, a painful, chronic inflammatory disease, significantly impairs the health and quality of life for over 10% of women of reproductive age. Tissue similar to the uterus lining grows outside the uterus, forming endometriotic lesions. This causes chronic pelvic pain as well as pain during menses, intercourse, urination and bowel movements. The symptoms often emerge in young adulthood, impacting education, career, and fertility. Current first-line treatments, including pain medications and hormonal contraceptives, provide inadequate relief for many patients or cause intolerable side effects which leaves a major unaddressed medical need for novel therapies.
Gesynta Pharma is developing vipoglanstat, a novel non-hormonal drug candidate for the treatment of endometriosis. Vipoglanstat targets mPGES-1, an enzyme upregulated in endometriotic lesions that drives both pain and lesion progression. Preclinical data has shown a marked reduction of endometriotic lesions and pain. The drug candidate has also demonstrated a favorable safety profile in previous clinical studies.
“Endometriosis forces millions of women to endure severe pain and other life-altering symptoms for years or even decades. Groundbreaking research revealing the central role of inflammation in the disease has opened promising new therapeutic pathways, bringing us closer to efficacious treatments without the side effects associated with current hormone-based therapies. Vipoglanstat represents a breakthrough in this frontier of novel non-hormonal treatment development,” comments Professor Linda Giudice, MD, PhD, a renowned international expert on endometriosis at the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF).
The financing round led by Innovestor Life Science included participation from existing and new investors such as Hadean Ventures, Industrifonden, Linc, RH Capital, Catalyze Capital, Stephen Industries and Amboy Street Ventures.
“This SEK 304 million funding round marks a pivotal milestone for Gesynta Pharma, demonstrating strong international investor confidence in our approach to treating endometriosis. With these funds, we will advance vipoglanstat towards being Phase III-ready, aiming to provide patients with a disease-modifying treatment option that overcomes the efficacy and tolerability limitations of current therapies,” said Patric Stenberg, CEO of Gesynta Pharma.
The upcoming European Phase II trial of vipoglanstat will enroll approximately 190 patients suffering from endometriosis. The trial will evaluate the efficacy and safety profile of two dose levels of vipoglanstat against placebo over four months’ administration.
”The substantial medical need for improved treatments of endometriosis combined with the commercial potential of vipoglanstat presents a compelling investment opportunity, and we are delighted to support Gesynta Pharma in the development of this potentially game-changing drug candidate,” said Pekka Simula, Partner at Innovestor Life Science fund.
Read more:
-
- Press release by Gesynta Pharma, 20.01.2025
For additional information:
Pekka Simula, Partner, Innovestor Life Science
+358 40 730 0445